中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2015年
5期
13-14
,共2页
英夫利昔单抗%炎症性肠病%应用疗效%影响因素
英伕利昔單抗%炎癥性腸病%應用療效%影響因素
영부리석단항%염증성장병%응용료효%영향인소
Infliximab%Inflammatory bowel disease%Application effect%Influence factors
目的：探讨英夫利昔单抗在治疗炎症性肠病中的疗效及影响因素。方法炎症性肠病患者62例随机分为对照组和观察组，各31例，其中对照组给予美沙拉秦进行治疗，观察组采用英夫利昔单抗进行治疗，比较两组患者治疗有效率、黏膜愈合率以及复发等情况，同时对影响患者的发病因素进行归纳分析。结果对比结果显示，对照组中治疗有效率为64.5%(20/31)，黏膜愈合率38.7%(12/31)，缓解率为29.0%(9/31)；观察组中治疗有效率为87.1%(27/31)，黏膜愈合率58.1%(18/31)，缓解率为9.7%(3/31)，两组对比差异有统计学意义(P<0.05)。结论在炎症性肠病临床治疗中，采用英夫利昔单抗的方法进行治疗具有较好的疗效，可有效改善患者临床症状，加快胃肠黏膜愈合，值得在临床上进行推广和应用。
目的：探討英伕利昔單抗在治療炎癥性腸病中的療效及影響因素。方法炎癥性腸病患者62例隨機分為對照組和觀察組，各31例，其中對照組給予美沙拉秦進行治療，觀察組採用英伕利昔單抗進行治療，比較兩組患者治療有效率、黏膜愈閤率以及複髮等情況，同時對影響患者的髮病因素進行歸納分析。結果對比結果顯示，對照組中治療有效率為64.5%(20/31)，黏膜愈閤率38.7%(12/31)，緩解率為29.0%(9/31)；觀察組中治療有效率為87.1%(27/31)，黏膜愈閤率58.1%(18/31)，緩解率為9.7%(3/31)，兩組對比差異有統計學意義(P<0.05)。結論在炎癥性腸病臨床治療中，採用英伕利昔單抗的方法進行治療具有較好的療效，可有效改善患者臨床癥狀，加快胃腸黏膜愈閤，值得在臨床上進行推廣和應用。
목적：탐토영부리석단항재치료염증성장병중적료효급영향인소。방법염증성장병환자62례수궤분위대조조화관찰조，각31례，기중대조조급여미사랍진진행치료，관찰조채용영부리석단항진행치료，비교량조환자치료유효솔、점막유합솔이급복발등정황，동시대영향환자적발병인소진행귀납분석。결과대비결과현시，대조조중치료유효솔위64.5%(20/31)，점막유합솔38.7%(12/31)，완해솔위29.0%(9/31)；관찰조중치료유효솔위87.1%(27/31)，점막유합솔58.1%(18/31)，완해솔위9.7%(3/31)，량조대비차이유통계학의의(P<0.05)。결론재염증성장병림상치료중，채용영부리석단항적방법진행치료구유교호적료효，가유효개선환자림상증상，가쾌위장점막유합，치득재림상상진행추엄화응용。
Objective To explore curative effect and influence factors of infliximab in the treatment of inflammatory bowel disease. Methods A total of 62 patients with inflammatory bowel disease were randomly divided into control group and observation group, with 31 cases in each group. The control group received mesalazine for treatment, and the observation group was treated by infliximab. The treatment effective rate, mucous membrane healing rate, and relapse of the two groups were compared. An inductive analysis was made on the influence factors of pathogenesis. Results The comparison showed that the treatment effective rate of the control group was 64.5% (20/31), the mucous membrane healing rate was 38.7% (12/31), and the remission rate was 29.0% (9/31). The observation group had the treatment effective rate as 87.1% (27/31), the mucous membrane healing rate as 58.1% (18/31), and the remission rate as 9.7% (3/31). The difference between the two groups had statistical significance (P<0.05). Conclusion The application of infliximab has good curative effect in clinical treatment for inflammatory bowel disease, and it can effectively improve patients’ clinical symptoms and accelerate rehabilitation of gastrointestinal mucosa. This method is worth promotion and application in clinic.
